GlobeNewswire by notified

CoinShares International Limited has been approved for listing on Nasdaq Stockholm

Share

Wednesday, 7 December 2022 |SAINT HELIER, Jersey -Nasdaq Stockholm's listing committee has today approved CoinShares International Limited's ("CoinShares" or the "Company") application for admission of the Company's shares to trading on Nasdaq Stockholm's main market. The approval is conditional upon customary conditions being fulfilled, for example that a prospectus is approved by and registered with the Swedish Financial Supervisory Authority ("SFSA") (Sw. Finansinspektionen) and that the requirements on liquidity of the Company's shares are fulfilled. First day of trading on Nasdaq Stockholm is scheduled to 19 December 2022 and last day of trading on Nasdaq First North Growth Market is scheduled to 16 December 2022.

The Company listed on Nasdaq First North Growth Market in March 2021 under the ticker "CS" and since the listing, the Company has worked strategically to develop the organization and its internal processes to meet the enhanced requirements placed on companies listed on Nasdaq Stockholm. The Company's board of directors and executive committee believe that a listing of the Company's shares on Nasdaq Stockholm will bring, amongst others, the following benefits:

  • by trading on the most senior marketplace in Sweden, enhance the regulatory profile, and thereby also the credibility, of the Group;
  • increase the Group's presence in the wider digital asset community which can contribute to higher levels of engagement with the Group's products and services;
  • increase awareness of the Group among analysts, prospective investors and the media;
  • make the Company's shares more attractive as a means of payment in connection with potential acquisitions; and
  • enabling investment in the Company's shares by institutional players who otherwise may be restricted to invest in companies that are listed on a MTF.

It is hoped that the above-mentioned benefits will contribute towards continued value creation for the Company's shareholders, and it is therefore the opinion of the board of directors and the executive committee team that a listing on Nasdaq Stockholm is in the interest of all shareholders of the Company.

There is no offering or issuance of new shares in connection with the Company's shares being admitted to trading on Nasdaq Stockholm. Shareholders of CoinShares do not need to take any action in connection with the change of listing venue. The shares will be traded under the same ticker (CS) and ISIN code (JE00BLD8Y945).

Prospectus
CoinShares will prepare a prospectus in connection with the admission to trading of the Company's shares on Nasdaq Stockholm. The prospectus is expected to be approved by the SFSA and published on CoinShares' website, https://coinshares.com/investor-relations/reports-portal/ on or about 14 December 2022.

Advisors
Baker McKenzie is the Company's legal advisor in connection with the admission to trading of the Company's shares on Nasdaq Stockholm.

About CoinShares
CoinShares is Europe's largest and longest standing digital asset investment firm, managing billions of dollars of assets on behalf of its client base. The Group is focused on expanding investor access to the digital asset ecosystem by pioneering new financial products and services that seek to provide trust and transparency when accessing this new asset class. CoinShares is publicly listed on the Nasdaq First North Growth Market under the ticker CS and the OTCQX under the ticker CNSRF.

For more information on CoinShares, please visit: https://coinshares.com

Company | +44 (0)1534 513 100 | enquiries@coinshares.com

Investor Relations | +44 (0)1534 513 100 | enquiries@coinshares.com

Certified Advisor – Mangold Fondkommission AB | +46 (0)8 503 015 50 | ca@mangold.se

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Landsbankinn hf.: Financial results of Landsbankinn for 20222.2.2023 14:36:13 CET | Press release

Landsbankinn's net profit in 2022 was ISK 17.0 billion. There was good growth in loans to corporates, ISK 92.0 billion or the equivalent of 10%, having regard for currency changes.Mortgage loans grew by 59.0 billion with demand decreasing in the fourth quarter.ROE in the fourth quarter of 2022 was 8.2%, compared with 10.5% ROE in the same quarter of 2021. ROE in 2022 was 6.3%, despite solid core earnings. The negative impact reducing profitability was mainly a decrease in the fair value of the Bank’s holding in Eyrir Invest hf. The Bank’s target ROE is 10% at a minimum. Operating expenses are stable. Landsbankinn topped the Icelandic Performance Satisfaction Index for banking customers the fourth year in a row. The Bank’s market share in the retail market has never been higher and measures over 40% for the first time. Loans in arrears are at a historic low and loans in arrears were 0.2% at the turn of the year.In 2022, the Bank paid a dividend of ISK 20.5 billion and ISK 14.1 billion i

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference2.2.2023 14:00:00 CET | Press release

BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET. A webcast of the fireside chat, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications. We operate with the conviction that

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa2.2.2023 14:00:00 CET | Press release

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody®sonelokimab in moderate-to-severe hidradenitis suppurativa Enrollment target of 210 patients randomized completed ahead of scheduleTop line results on the primary endpoint, for the novel IL-17A and IL-17F inhibitor Nanobody® sonelokimab, expected mid-2023First registered randomized trial in HS to use HiSCR75 as the primary endpoint; trial also includes adalimumab as an active reference armThe trial will proceed to its 24-week completion, including placebo patients re-randomized to sonelokimab and adalimumab patients switched to sonelokimab, with final read out expected, as planned, by Q4 2023 ZUG, Switzerland, February 2, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has completed enrollment of the target 210 pa

Danske Bank A/S, transactions by persons discharging managerial responsibilities2.2.2023 13:53:28 CET | Press release

2February 2023 Notification no. 1/2023 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation For further details, please find the attached template for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Attachments Appendix - Martin Blessing - buyAppendix - Aleksandras Cicasovas - buyAppendix - Jacob Dahl - buyAppendix - Jan Thorsgaard Nielsen - buyAppendix - Lars-Erik Brenøe - buy

Danske Bank A/S, ledende medarbejderes transaktioner2.2.2023 13:53:28 CET | pressemeddelelse

2. februar 2023 Indberetning nr. 1/2023 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug For yderligere detaljer henvises til det vedhæftede skema, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Vedhæftede filer Bilag - Martin Blessing - købBilag - Aleksandras Cicasovas - købBilag - Jacob Dahl - købBilag - Jan Thorsgaard Nielsen - købBilag - Lars-Erik Brenøe - køb